Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'

Ann Rheum Dis. 2023 Apr;82(4):e81. doi: 10.1136/annrheumdis-2021-219872. Epub 2021 Jan 28.

Authors

Carlo Perricone¹, Elena Bartoloni¹, Giacomo Cafaro¹, Roberto Caporali², Roberto Gerli³

Affiliations

¹ Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
² Department of Clinical Sciences and Community Health, ASS G Pini, University of Milan, Milano, Italy.
³ Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy roberto.gerli@unipg.it.

PMID: 33509794
DOI: 10.1136/annrheumdis-2021-219872

No abstract available

Keywords: Covid-19; gout; inflammation.

Publication types

Letter
Comment

MeSH terms

Anti-Inflammatory Agents / therapeutic use
COVID-19*
Colchicine / therapeutic use
Gout Suppressants / therapeutic use
Gout* / drug therapy
Humans

Substances

Colchicine
Gout Suppressants
Anti-Inflammatory Agents